Much research has focused on finding novel prognostic biomarkers for triple negative breast
cancer (TNBC), whereas only scattered information about the relation between …

Abstract Background Triple Negative breast cancer (TNBC) includes a heterogeneous group
of tumors with different clinico-pathological features, molecular alterations and treatment …

Background Triple negative breast cancer (TNBC) is an aggressive disease, but recent
studies have identified heterogeneity in patient outcomes. However, the utility of histologic …

Triple‐negative breast cancer (TNBC) remains a major challenge in breast cancer
management. Continuing research in the past years aimed at understanding the biology of …

Purpose To examine the clinicopathologic characteristics and survival outcomes of different
histologic types of triple-negative breast cancer (TNBC). Methods We used the SEER …

Simple Summary Breast cancers that lack expression of the predictive markers oestrogen
receptor, progesterone receptor and human epidermal growth factor receptor-2 are known …

Background This study assesses outcome in terms of disease-free survival (DFS) and
overall survival (OS) of special types of triple-negative breast cancer (TNBC). Patients and …

Introduction Triple negative breast cancer (TNBC) has a poorer survival, despite a higher
response rate to neoadjuvant chemotherapy. The purpose of this study was to identify the …

Purpose Triple-negative breast cancer (TNBC) is an aggressive disease lacking specific
biomarkers to guide treatment decisions. We evaluated the combined prognostic impact of …

Background Triple-negative breast cancer (TNBC) has a poor prognosis, even in its early
stages. In the absence of postoperative targeted treatments, intensive adjuvant …